A clustered family history of breast, ovarian, and colon cancers appropriately triggered germline testing, with BRCA1 mutation status informing individualized risk stratification and counseling.

Breast cancer is a prevalent cancer in women across the globe. Although a majority of the instances are isolated, hereditary cases associated with genetic mutations are found in 5-10 percent. Of these ...

Fast track designation enables more frequent FDA interactions and may facilitate priority review or accelerated approval pathways if subsequent efficacy benchmarks are achieved. Polθ inhibition ...

FDA fast track covers ART6043 plus olaparib in PARP inhibitor–naïve gBRCAm, HER2-negative locally advanced/metastatic breast cancer, enabling earlier FDA engagement and potential priority ...